Discover 176 paid clinical trials in Maine. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Maine offers nearby opportunities for both healthy volunteers seeking paid studies and individuals with specific health conditions to participate in valuable research. Major research centers in Portland, Bangor, and Augusta are actively recruiting, providing easy access to advanced medical care and new treatment options.
Filter
1
Filter results
Results: 176
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Scarborough ME, South Weymouth MA, Boston MA,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase 3, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: Saint John, South Portland ME, West Haven CT,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase 3, Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Westbrook ME, Worcester MA, Hartford CT, New York NY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase 3, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Brewer ME, Burlington MA, Manchester NH, Worcester MA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT06031688
Phase 2, Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
for
Low Grade Astrocytoma, Low Grade Glioma,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 2 - 21
Code: NCT04166409
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
for
Hodgkin Lymphoma in Remission, Leukemia in Remission,
Location: Scarborough ME, Boston MA, Providence RI, New Haven CT,
Sponsor: Children's Oncology Group
Sex: All
Age: 0+
Code: NCT01790152
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
for
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 25
Code: NCT03959085
Phase 3, Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
for
Embryonal Rhabdomyosarcoma,
Location: Halifax, Scarborough ME, Boston MA, Providence RI,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT05304585
Phase 3, Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
for
Ovarian Carcinoma
Location: Portland ME, Scarborough ME, Boston MA, Providence RI,
Sponsor: NRG Oncology
Sex: Female
Age: 35 - 50
Code: NCT04251052
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
for
Atrial Fibrillation (AF)
Location: Mira Road, Halifax, Bangor ME, Fall River MA, Boston MA,
Sponsor: Anthos Therapeutics, Inc.
Sex: All
Age: 65+
Code: NCT05712200
Phase 3, Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT04322318
Phase 2, Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Saint John, Damariscotta ME, Brunswick ME, Augusta ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04269902
Phase 3, Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Brewer ME, Gloucester MA, South Weymouth MA, Beverly MA,